Genetic and transcriptional evolution alters cancer cell line drug response

Uri Ben‐David(Tel Aviv University), Todd R. Golub(Broad Institute), Helen Tang(University of Pennsylvania), Guillaume Kugener(Broad Institute), Joshua M. Dempster(Broad Institute), Yaara Oren(Tel Aviv University), Anwesha Nag(Dana-Farber Cancer Institute), Anthony J. Garrity(Broad Institute), Benjamin A. Siranosian(Broad Institute), Beth A. Cimini(Broad Institute), Gavin Ha(AstraZeneca (United Kingdom)), Rameen Beroukhim(Broad Institute), Francisca Vázquez(Broad Institute), Aaron R. Thorner(Center for Cancer Research), Matthew Meyerson(Broad Institute), Craig A. Strathdee(Broad Institute), Bang Wong(Broad Institute), Joshua A. Bittker, Kunihiko Hinohara(Broad Institute), Aviad Tsherniak(Broad Institute), Ryan O’Rourke(Broad Institute), Andrew A. Tubelli(Broad Institute), Nicholas Lyons(Broad Institute), Chet Birger(Broad Institute), Pratiti Bandopadhayay(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Peter Tsvetkov(Broad Institute), Yosef E. Maruvka(Technion – Israel Institute of Technology), Mahmoud Ghandi(Broad Institute), Robert Burns(Dana-Farber Cancer Institute), Gad Getz(Broad Institute)
Nature
August 1, 2018
Cited by 943


Related Papers